

NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: **Stock**

Company 2022/08/12 17:30:57

Price
80.10
CHF

Difference  **-1.16% (-0.94)**



Contact Details

NOVARTIS AG Tel: 41-61-324-11-11
 -- Fax: 41-61-324-80-01
 Lichtstrasse 35 Web: <http://www.novartis.com>
 4056 Basel E-mail: -

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	41,655,955,000		26,229,448,000		28,570,198,000	
Common stock capital		820,946,000		807,046,000		906,375,000
Fixed assets	82,154,750,000		90,619,018,000		86,095,030,000	
Equity capital of a company		61,796,015,000		50,089,910,000		53,792,810,000
Cash and cash equivalents	11,304,638,000		8,537,189,000		10,760,305,000	
Accrued liabilities		4,279,671,000		4,897,966,000		5,247,488,000
Other assets	-		-		-	
Current liabilities		27,524,019,000		29,222,503,000		27,369,444,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		34,490,672,000		37,536,052,000		33,502,973,000
Different income		-		-		-
Other liabilities		1,343,946,000		1,231,342,000		1,174,608,000
Total assets	123,810,706,000	123,810,706,000	116,848,466,000	116,848,466,000	114,665,228,000	114,665,228,000

Balance notes

	2021	2020	2019
Accounting standard	IFRS	IFRS	IFRS
Employees	104,323	105,794	103,914
Equity ratio	50.03%	42.92%	46.98%
Debt-equity ratio	99.86%	133.00%	112.87%

Others

	2021	2020	2019
Tax Expense Rate	19.62%	19.63%	21.65%

Income statement

	2021	2020	2019
Turnover	47,199,917,000	45,672,013,000	47,202,693,000
Net income	21,961,593,000	7,576,491,000	7,097,596,000
EBIT	10,947,981,493	9,695,014,961	9,144,999,764
Operating income before taxes	9,872,248,000	8,639,940,000	8,229,514,000
Cash Flow	13,778,909,000	12,812,079,000	13,540,289,000
Net interest income	-766,155,000	-780,926,000	-656,890,000
Research and development expenses	8,722,101,000	8,428,752,000	9,343,545,000
Income taxes	1,937,330,000	1,696,075,000	1,781,852,000
Result from investments in subsidiaries, associates and other	14,023,932,000	631,687,000	654,902,000
Revenues per employee	465,606	444,270	467,466

Board of Directors

Andreas von Planta	Member of the administrative board
Charles Sawyers	Member of the administrative board
Nancy Andrews	Member of the administrative board
Simon Moroney	Member of the administrative board
Ana de Pro Gonzalo	Member of the administrative board
Bridgette Heller	Member of the administrative board
Daniel Hochstrasser	Member of the administrative board
Frans van Houten	Member of the administrative board
Mary Doherty	Member of the administrative board
Patrice Bula	Member of the administrative board
Ton Büchner	Member of the administrative board
William Winters	Member of the administrative board
Hans Jörg Reinhardt	Chairman of the administrative board

Members of Management Board

Vasant Narasimhan, M.D.	Chairman of Managing Board
James E. Bradner	Member of Executive Committee
Klaus Moosmayer	Member of Executive Committee
Steffen Lang	Member of Executive Committee
Susanne Schaffert	Member of Executive Committee
Harry Kirsch	Member of Executive Committee
John Tsai, M.D.	Member of Executive Committee
Karen L. Hale	Member of Executive Committee
Marie-France Tschudin	Member of Executive Committee
Richard Saynor	Member of Executive Committee
Rob Kowalski	Member of Executive Committee
Robert Weltevreden	Member of Executive Committee